Kyongbo Pharmaceutical Co Ltd banner

Kyongbo Pharmaceutical Co Ltd
KRX:214390

Watchlist Manager
Kyongbo Pharmaceutical Co Ltd Logo
Kyongbo Pharmaceutical Co Ltd
KRX:214390
Watchlist
Price: 7 150 KRW -9.95% Market Closed
Market Cap: ₩171B

Profitability Summary

Kyongbo Pharmaceutical Co Ltd's profitability score is 43/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

43/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

43/100
Profitability
Score
43/100
Profitability
Score

Margins

Earnings Waterfall
Kyongbo Pharmaceutical Co Ltd

Margins Comparison
Kyongbo Pharmaceutical Co Ltd Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
KR
Kyongbo Pharmaceutical Co Ltd
KRX:214390
170.9B KRW
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
856.7B USD
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
566.8B USD
Loading...
Loading...
Loading...
CH
Roche Holding AG
SIX:ROG
243.3B CHF
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
282.6B USD
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
222.2B CHF
Loading...
Loading...
Loading...
IE
Endo International PLC
LSE:0Y5F
237.1B USD
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
153.4B USD
Loading...
Loading...
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
115.7B USD
Loading...
Loading...
Loading...

Return on Capital

Return on Capital Comparison
Kyongbo Pharmaceutical Co Ltd Competitors

Country Company Market Cap ROE ROA ROCE ROIC
KR
Kyongbo Pharmaceutical Co Ltd
KRX:214390
170.9B KRW
Loading...
Loading...
Loading...
Loading...
US
Eli Lilly and Co
NYSE:LLY
856.7B USD
Loading...
Loading...
Loading...
Loading...
US
Johnson & Johnson
NYSE:JNJ
566.8B USD
Loading...
Loading...
Loading...
Loading...
CH
Roche Holding AG
SIX:ROG
243.3B CHF
Loading...
Loading...
Loading...
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP
Loading...
Loading...
Loading...
Loading...
US
Merck & Co Inc
NYSE:MRK
282.6B USD
Loading...
Loading...
Loading...
Loading...
CH
Novartis AG
SIX:NOVN
222.2B CHF
Loading...
Loading...
Loading...
Loading...
IE
Endo International PLC
LSE:0Y5F
237.1B USD
Loading...
Loading...
Loading...
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK
Loading...
Loading...
Loading...
Loading...
US
Pfizer Inc
NYSE:PFE
153.4B USD
Loading...
Loading...
Loading...
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
115.7B USD
Loading...
Loading...
Loading...
Loading...

Free Cash Flow

Free Cash Flow Analysis
Kyongbo Pharmaceutical Co Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett